keyword
MENU ▼
Read by QxMD icon Read
search

Evolocumab

keyword
https://www.readbyqxmd.com/read/29411675/pcsk9-inhibitors-a-non-statin-cholesterol-lowering-treatment-option
#1
Gregory S Pokrywka
Elevated low-density lipoprotein cholesterol (LDL-C) plays a major role in the development of atherosclerotic cardiovascular disease. Statins are the first-line treatment to lower LDL-C in patients with hypercholesterolemia; however, some high cardiovascular risk patients may have inadequate responses to statin therapy or are intolerant to statins, and may need additional and/or alternative non-statin therapies to further reduce their LDL-C levels. Monoclonal antibodies that inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9), a key regulator of circulating LDL-C levels, have received considerable attention as promising non-statin therapeutic options for the management of hypercholesterolemia...
February 7, 2018: Postgraduate Medicine
https://www.readbyqxmd.com/read/29407597/role-of-dual-lipid-lowering-therapy-in-coronary-atherosclerosis-regression-evidence-from-recent-studies
#2
REVIEW
Felice Gragnano, Paolo Calabrò
Despite recent therapeutic advances, there is an unmet need in cardiovascular disease prevention. Clinical trials and meta-analyses have established that LDL-C lowering, particularly by statin therapy, reduces the progression of coronary atherosclerosis and the risk of coronary events. Insufficient LDL-C reduction and high residual risk in a significant proportion of statin-treated patients signify that additional therapies are required to deliver more effective coronary care. Pharmacological inhibition of cholesterol absorption (with ezetimibe) and PCSK9 activity (with evolocumab or alirocumab) provides potentially useful approaches for the therapeutic modulation of LDL-C metabolism in statin-treated patients...
January 17, 2018: Atherosclerosis
https://www.readbyqxmd.com/read/29398508/lipoprotein-apheresis-affects-lipoprotein-particle-subclasses-more-efficiently-compared-to-the-pcsk9-inhibitor-evolocumab-a-pilot-study
#3
Knut Tore Lappegård, Christian Abendstein Kjellmo, Stefan Ljunggren, Karin Cederbrant, Maritha Marcusson-Ståhl, Monica Mathisen, Helen Karlsson, Anders Hovland
Lipoprotein apheresis and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are last therapeutic resorts in patients with familial hypercholesterolemia (FH). We explored changes in lipoprotein subclasses and high-density lipoprotein (HDL) function when changing treatment from lipoprotein apheresis to PCSK9 inhibition. We measured the levels of low-density lipoprotein (LDL) and HDL particle subclasses, serum amyloid A1 (SAA1), paraoxonase-1 (PON1) activity and cholesterol efflux capacity (CEC) in three heterozygous FH patients...
January 4, 2018: Transfusion and Apheresis Science
https://www.readbyqxmd.com/read/29377473/effect-of-the-pcsk9-monoclonal-antibodies-on-new-onset-diabetes-mellitus-and-glucose-metabolism-a-systematic-review-and-meta-analysis
#4
Ye-Xuan Cao, Hui-Hui Liu, Qiu-Ting Dong, Sha Li, Jian-Jun Li
AIMS: To investigate the effect of two clinically applied proprotein convertase subtilisin/kexin type 9 monoclonal antibody (PCSK9-mAb) on glycaemia and new-onset diabetes mellitus (NODM). MATERIALS AND METHODS: PubMed, MEDLINE, Embase, Cochrane databases and ClinicalTrials.gov websites were systematically searched for randomized controlled trials that reported the fasting plasma glucose (FPG), Hemoglobin A1c (HbA1c) or NODM incidence. Risk ratios (RR) for NODM and Mean Difference (MD) for FPG and HbA1c with 95% confidence intervals (CI) were calculated using a fixed-effect model...
January 27, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29365947/a-comparison-of-the-efficacy-and-tolerability-of-the-pcsk9-inhibitors-alirocumab-and-evolocumab-in-routine-lipid-clinic-practice
#5
Alan Jones, Kate Peers, Sud Ramachandran, Ateeq Syed
No abstract text is available yet for this article.
August 2017: Atherosclerosis
https://www.readbyqxmd.com/read/29365888/combination-therapy-of-evolocumab-and-ldl-apheresis-in-patients-with-heterozygous-familial-hypercholesterolemia-a-case-series
#6
José Carlos Alarcón García, Aurora González Estrada, Ana Camacho Carrasco, Paula García Ocaña, María Carmen Alarcón Garcelan, Fatima Espinosa-Torre, Verónica Alfaro-Lara, Ovidio Muñiz Grijalvo
No abstract text is available yet for this article.
August 2017: Atherosclerosis
https://www.readbyqxmd.com/read/29365437/the-ldl-receptor-ldlr-is-a-major-driver-of-ldl-cholesterol-levels-in-homozygous-fh-hofh-patients-treated-with-evolocumab
#7
Thedrez Aurelie, Dirk Blom, Croyal Mikael, Krempf Michel, Raal Frederick, Lambert Gilles
No abstract text is available yet for this article.
August 2017: Atherosclerosis
https://www.readbyqxmd.com/read/29361723/treatment-strategy-for-dyslipidemia-in-cardiovascular-disease-prevention-focus-on-old-and-new-drugs
#8
Donatella Zodda, Rosario Giammona, Silvia Schifilliti
Prevention and treatment of dyslipidemia should be considered as an integral part of individual cardiovascular prevention interventions, which should be addressed primarily to those at higher risk who benefit most. To date, statins remain the first-choice therapy, as they have been shown to reduce the risk of major vascular events by lowering low-density lipoprotein cholesterol (LDL-C). However, due to adherence to statin therapy or statin resistance, many patients do not reach LDL-C target levels. Ezetimibe, fibrates, and nicotinic acid represent the second-choice drugs to be used in combination with statins if lipid targets cannot be reached...
January 21, 2018: Pharmacy (Basel, Switzerland)
https://www.readbyqxmd.com/read/29353350/clinical-pharmacokinetics-and-pharmacodynamics-of-evolocumab-a-pcsk9-inhibitor
#9
REVIEW
Sreeneeranj Kasichayanula, Anita Grover, Maurice G Emery, Megan A Gibbs, Ransi Somaratne, Scott M Wasserman, John P Gibbs
Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases plasma low-density lipoprotein cholesterol (LDL-C) by decreasing expression of the LDL receptor on hepatic cells. Evolocumab is a human monoclonal immunoglobulin G2 that binds specifically to human PCSK9 to reduce LDL-C. Evolocumab exhibits nonlinear kinetics as a result of binding to PCSK9. Elimination is predominantly through saturable binding to PCSK9 at lower concentrations and a nonsaturable proteolytic pathway at higher concentrations. The effective half-life of evolocumab is 11-17 days...
January 20, 2018: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/29327884/cognitive-function-in-a-randomized-trial-of-evolocumab
#10
Robert P Giugliano, Marc S Sabatine, Brian R Ott
No abstract text is available yet for this article.
November 16, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29327883/cognitive-function-in-a-randomized-trial-of-evolocumab
#11
Paolo Calabrò, Felice Gragnano, Matteo Pirro
No abstract text is available yet for this article.
November 16, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29299849/lipid-management-in-chronic-kidney-disease-systematic-review-of-pcsk9-targeting
#12
REVIEW
BinBin Zheng-Lin, Alberto Ortiz
Cardiovascular disease is the leading cause of death in patients with chronic kidney disease (CKD) and CKD is considered a coronary artery disease risk equivalent. So far, statins have been the mainstay of primary and secondary prevention of cardiovascular disease in the general population. However, their benefit on outcomes is limited and controversial in CKD patients and new therapeutic approaches to reduce cardiovascular risk are needed. Monoclonal antibodies targeting proprotein convertase subtilisin/kexin 9 (PCSK9) reduce low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) in high-risk populations and cardiovascular events in secondary prevention...
January 3, 2018: Drugs
https://www.readbyqxmd.com/read/29284604/homozygous-familial-hypercholesterolemia-patients-with-identical-mutations-variably-express-the-ldlr-low-density-lipoprotein-receptor-implications-for-the-efficacy-of-evolocumab
#13
Aurélie Thedrez, Dirk J Blom, Stéphane Ramin-Mangata, Valentin Blanchard, Mikaël Croyal, Kevin Chemello, Brice Nativel, Matthieu Pichelin, Bertrand Cariou, Steeve Bourane, Lihua Tang, Michel Farnier, Frederick J Raal, Gilles Lambert
OBJECTIVE: Evolocumab, a PCSK9 (proprotein convertase subtilisin kexin type 9)-neutralizing antibody, lowers low-density lipoprotein cholesterol (LDL-C) in homozygous familial hypercholesterolemic (HoFH) patients with reduced LDLR (low-density lipoprotein receptor) function. However, their individual responses are highly variable, even among carriers of identical LDLR genetic defects. We aimed to elucidate why HoFH patients variably respond to PCSK9 inhibition. APPROACH AND RESULTS: Lymphocytes were isolated from 22 HoFH patients enrolled in the TAUSSIG trial...
December 28, 2017: Arteriosclerosis, Thrombosis, and Vascular Biology
https://www.readbyqxmd.com/read/29281604/results-of-the-glagov-trial
#14
REVIEW
Steven E Nissen, Stephen J Nicholls
Statins therapy reduces atheroma in proportion to the reduction of low-density lipoprotein cholesterol (LDL-C). Proprotein convertase subtilisin--kexin type 9 (PCSK9) inhibitors are a new class of injectable human monoclonal antibodies shown to lower LDL-C when added to statin therapy. In a randomized, double-blind, placebo-controlled study, 968 patients with symptomatic coronary artery disease were treated with statins alone or combined with the PCSK9 inhibitor, evolocumab, and assessed for change in percent, total volume, and regression of coronary atheroma...
December 2017: Cleveland Clinic Journal of Medicine
https://www.readbyqxmd.com/read/29273581/mortality-differences-associated-with-treatment-responses-in-cantos-and-fourier-insights-and-implications
#15
Paul M Ridker
Similarities and differences in two contemporary post-randomization on-treatment analyses from the FOURIER and CANTOS trials may provide insight into what factors drive reductions in cardiovascular mortality and all-cause mortality among atherosclerosis patients already treated with high intensity statins. In the first paper, the FOURIER investigators elegantly demonstrate that lower is better for low-density lipoprotein cholesterol (LDLC) after adjunctive therapy with the PCSK9 inhibitor evolocumab1 For the FOURIER primary endpoint (a composite of myocardial infarction, stroke, coronary revascularization, unstable angina, or cardiovascular death), there was a highly significant monotonic relationship between sequentially lower achieved LDLC concentrations and lower cardiovascular risk, extending even to those with on-treatment LDLC below 20 mg/dL...
December 22, 2017: Circulation
https://www.readbyqxmd.com/read/29231064/pharmacokinetics-pharmacodynamics-and-clinical-efficacy-of-non-statin-treatments-for-hypercholesterolemia
#16
REVIEW
Arrigo F G Cicero, Marilisa Bove, Claudio Borghi
Hypercholesterolemia is the main modifiable risk factor for atherosclerosis progression and cardiovascular disease (CVD) development. Its pharmacological management is usually based on the prescription of statins, that in some cases are not however fully effective to reach the desired Low-Density-Lipoproteins cholesterol (LDL-C) target, or are not tolerated by patients due to side effects. Areas covered: This manuscript summarizes the basic properties of the emerging new classes of lipid-lowering drugs such as ezetimibe, Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors, and Microsomal Triglyceride Transfer Protein (MTP) inhibitors, also citing new drugs in development...
January 2018: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/29223954/effect-of-pcsk9-inhibitors-on-clinical-outcomes-in-patients-with-hypercholesterolemia-a-meta-analysis-of-35-randomized-controlled-trials
#17
REVIEW
Aris Karatasakis, Barbara A Danek, Judit Karacsonyi, Bavana V Rangan, Michele K Roesle, Thomas Knickelbine, Michael D Miedema, Houman Khalili, Zahid Ahmad, Shuaib Abdullah, Subhash Banerjee, Emmanouil S Brilakis
BACKGROUND: We sought to examine the efficacy and safety of 2 PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors: alirocumab and evolocumab. METHODS AND RESULTS: We performed a systematic review and meta-analysis of randomized controlled trials comparing treatment with and without PCSK9 inhibitors; 35 randomized controlled trials comprising 45 539 patients (mean follow-up: 85.5 weeks) were included. Mean age was 61.0±2.8 years, and mean baseline low-density lipoprotein cholesterol was 106±22 mg/dL...
December 9, 2017: Journal of the American Heart Association
https://www.readbyqxmd.com/read/29221604/effect-of-evolocumab-on-lipoprotein-particles
#18
Peter P Toth, Naveed Sattar, Dirk J Blom, Seth S Martin, Steven R Jones, Maria Laura Monsalvo, Mary Elliott, Mike Davis, Ransi Somaratne, David Preiss
The level of low-density lipoprotein cholesterol (LDL-C) reflects the cholesterol carried mainly by low-density lipoprotein particles (LDL-P). LDL-C, however, does not always correlate with LDL-P because of the variable amounts of cholesterol per particle. Consideration of LDL-P concentrations in addition to LDL-C may help guide therapeutic decisions in a select number of patients. Evolocumab is a fully human monoclonal antibody directed against proprotein convertase subtilisin-kexin type 9 that lowers both LDL-C and cardiovascular events...
November 8, 2017: American Journal of Cardiology
https://www.readbyqxmd.com/read/29183072/evolocumab-reduces-cardiovascular-risk-regardless-of-diabetes-status
#19
Anita Slomski
No abstract text is available yet for this article.
November 28, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/29181773/budget-impact-analysis-of-pcsk9-inhibitors-for-the-management-of-adult-patients-with-heterozygous-familial-hypercholesterolemia-or-clinical-atherosclerotic-cardiovascular-disease
#20
Usha G Mallya, Susan H Boklage, Andrew Koren, Thomas E Delea, C Daniel Mullins
OBJECTIVE: The aim of this study was to assess the budget impact of introducing the proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) alirocumab and evolocumab to market for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular (CV) disease requiring additional lowering of low-density lipoprotein cholesterol (LDL-C). METHODS: A 3-year model estimated the costs of lipid-modifying therapy (LMT) and CV events to a hypothetical US health plan of 1 million members, comparing two scenarios-with and without the availability of PCSK9i as add-on therapy to statins...
November 27, 2017: PharmacoEconomics
keyword
keyword
56929
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"